 |
|
Risk of Stroke Associated With Abciximab Among Patients Undergoing Percutaneous Coronary Intervention
K. Martijn Akkerhuis, MD;
Jaap W. Deckers, MD;
A. Michael Lincoff, MD;
James E. Tcheng, MD;
Eric Boersma, PhD;
Keaven Anderson, PhD;
Craig Balog, BS;
Robert M. Califf, MD;
Eric J. Topol, MD;
Maarten L. Simoons, MD
JAMA. 2001;286:78-82.
Context Abciximab, a potent inhibitor of the platelet glycoprotein IIb/IIIa receptor, reduces thrombotic complications in patients undergoing percutaneous coronary intervention (PCI). Because of its potent inhibition of platelet aggregation, the effect of abciximab on risk of stroke is a concern.
Objective To determine whether abciximab use among patients undergoing PCI is associated with an increased risk of stroke.
Design Combined analysis of data from 4 double-blind, placebo-controlled, randomized trials (EPIC, CAPTURE, EPILOG, and EPISTENT) conducted between November 1991 and October 1997 at a total of 257 academic and community hospitals in the United States and Europe.
Patients A total of 8555 patients undergoing PCI with or without stent deployment for a variety of indications were randomly assigned to receive a bolus and infusion of abciximab (n = 5476) or matching placebo (n = 3079). One treatment group in EPIC received a bolus of abciximab only.
Main Outcome Measure Risk of hemorrhagic and nonhemorrhagic stroke within 30 days of treatment among abciximab and placebo groups.
Results No significant difference in stroke rate was observed between patients assigned abciximab (n = 22 [0.40%]) and those assigned placebo (n = 9 [0.29%]; P = .46). Excluding the EPIC abciximab bolus-only group, there were 9 strokes (0.30%) among 3023 patients who received placebo and 15 (0.32%) in 4680 patients treated with abciximab bolus plus infusion, a difference of 0.02% (95% confidence interval [CI], -0.23% to 0.28%). The rate of nonhemorrhagic stroke was 0.17% in patients treated with abciximab and 0.20% in patients treated with placebo (difference, -0.03%; 95% CI, -0.23% to 0.17%), and the rates of hemorrhagic stroke were 0.15% and 0.10%, respectively (difference, 0.05%; 95% CI, -0.11% to 0.21%). Among patients treated with abciximab, the rate of hemorrhagic stroke in patients receiving standard-dose heparin in EPIC, CAPTURE, and EPILOG was higher than in those receiving low-dose heparin in the EPILOG and EPISTENT trials (0.27% vs 0.04%; P = .057).
Conclusions Abciximab in addition to aspirin and heparin does not increase the risk of stroke in patients undergoing PCI. Patients undergoing PCI and treated with abciximab should receive low-dose, weight-adjusted heparin.
Author Affiliations: Thoraxcenter, University Hospital Rotterdam, Rotterdam, the Netherlands (Drs Akkerhuis, Deckers, Boersma, and Simoons); Cleveland Clinic Foundation, Cleveland, Ohio (Drs Lincoff and Topol and Mr Balog); Duke Clinical Research Institute, Durham, NC (Drs Tcheng and Califf); and Centocor Inc, Malvern, Pa (Dr Anderson).
RELATED ARTICLE
July 4, 2001
JAMA. 2001;286(1):111-112.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Periprocedural Stroke and Cardiac Catheterization
Hamon et al.
Circulation 2008;118:678-683.
FULL TEXT
Ischemic strokes after cardiac catheterization: opportune thrombolysis candidates?
Khatri and Kasner
Arch Neurol 2006;63:817-821.
ABSTRACT
| FULL TEXT
Emergency Administration of Abciximab for Treatment of Patients With Acute Ischemic Stroke: Results of a Randomized Phase 2 Trial
Abciximab Emergent Stroke Treatment Trial Investi
Stroke 2005;36:880-890.
ABSTRACT
| FULL TEXT
Characteristics of cerebrovascular accidents after percutaneous coronary interventions
Dukkipati et al.
J Am Coll Cardiol 2004;43:1161-1167.
ABSTRACT
| FULL TEXT
Coupling Drug and Catheter Therapy for Myocardial Infarction
Lincoff
JAMA 2004;291:1000-1002.
FULL TEXT
Intraarterial Administration of Abciximab for Thromboembolic Events Occurring during Aneurysm Coil Placement
Mounayer et al.
Am. J. Neuroradiol. 2003;24:2039-2043.
ABSTRACT
| FULL TEXT
Risk of intracranial haemorrhage with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction: Dichotomous response as a function of age in the GUSTO V trial
Savonitto et al.
Eur Heart J 2003;24:1807-1814.
ABSTRACT
| FULL TEXT
Management of Patients Undergoing Percutaneous Coronary Revascularization
Levine et al.
ANN INTERN MED 2003;139:123-136.
ABSTRACT
| FULL TEXT
Deaths associated with platelet glycoprotein IIb/IIIa inhibitor treatment
Brown
Heart 2003;89:535-537.
ABSTRACT
| FULL TEXT
Stroke Complicating Percutaneous Coronary Interventions: Incidence, Predictors, and Prognostic Implications
Fuchs et al.
Circulation 2002;106:86-91.
ABSTRACT
| FULL TEXT
Intracerebral Hemorrhages Associated With Neurointerventional Procedures Using a Combination of Antithrombotic Agents Including Abciximab
Qureshi et al.
Stroke 2002;33:1916-1919.
ABSTRACT
| FULL TEXT
Post-PCI Stroke Risk Not Higher with Abciximab
Journal Watch Cardiology 2001;2001:6-6.
FULL TEXT
|
